Sanofi’s global revenues dropped 6.7% to $11.6 billion in Q3, a disappointment. The company said a modest 2.8% increase in emerging markets sales was not enough to offset revenue shortfalls from drugs that have lost their patent protection. Sanofi’s China revenues actually rose during the quarter: they were up 5% to $477 million, though 5% represents a smaller increase than the double-digit percentage that has been the norm. More details.... Stock Symbol: (NYSE: SNY) Share this with colleagues: // //